Strongbridge Biopharma plc Announces Presentations at Two Upcoming Investor Conferences
DUBLIN, Ireland and TREVOSE, Pa., Aug. 28, 2018 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announced that Matthew Pauls, president and chief executive officer, is scheduled to present a corporate overview at two upcoming investor conferences. The details are as follows:
H.C. Wainwright 20th Annual Global Investment Conference Date: Wednesday, September 5, 2018 Time: 12:05 p.m. ET Location: St. Regis Hotel, New York, NY
2018 Wells Fargo Healthcare Conference Date: Thursday, September 6, 2018 Time: 3:05 p.m. ET Location: Westin Copley Place, Boston, MA
Both presentations will be webcast live and available on the “Events & Presentations” page in the Investor section of the Company’s website at www.strongbridgebio.com.
About Strongbridge BiopharmaStrongbridge Biopharma is a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs. Strongbridge’s rare endocrine franchise includes MACRILEN™ (macimorelin), the first and only FDA-approved oral drug indicated for the diagnosis of adult growth hormone deficiency, RECORLEV™ (levoketoconazole), a cortisol synthesis inhibitor currently being studied in Phase 3 clinical studies for the treatment of endogenous Cushing’s syndrome, and veldoreotide extended release, a pre-clinical next-generation somatostatin analog being investigated for the treatment of acromegaly and potential additional applications in other conditions amenable to somatostatin receptor activation. MACRILEN has orphan drug exclusivity in the United States, and both RECORLEV and veldoreotide have received orphan drug designation from the FDA and the European Medicines Agency. The Company’s rare neuromuscular franchise includes KEVEYIS® (dichlorphenamide), the first and only FDA-approved treatment for hyperkalemic, hypokalemic, and related variants of primary periodic paralysis. KEVEYIS has orphan drug exclusivity in the United States.
Corporate and Media Relations Elixir Health Public Relations Lindsay Rocco +1 862-596-1304 email@example.com
U.S.:Solebury Trout Marcy Nanus +1 646-378-2927 firstname.lastname@example.org
Europe:First HouseGeir Arne Drangeid +47 913 10 458 email@example.com Strongbridge Biopharma plc900 Northbrook Drive Suite 200 Trevose, PA 19053 Tel. +1 610-254-9200 Fax. +1 215-355-7389